In Vitro: Imvotamab (1-10000 pM) has Killing effect on rituximab-resistant ramos cells. Imvotamab (0.1-1000 pM) has Killing effect on standard ramos cells. Imvotamab (1-1000 pM) significantly reduces the content of IL-6, IL-2, IFNγ and TNFα in cytokine release syndrome.
In Vivo: Imvotamab (0.001-10 mg/kg; single dose) significantly reduces the percent of B cells in cynomolgus monkeys. Imvotamab (25 mg/kg) promotes the depletion of B cells in spleen and lymphoid tissue without significant adverse effects in non-human primate.